Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Recurrence 1Prostatic Neoplasms 1Neoplasms 1Liver Neoplasms 1Leukemia, Myeloid, Acute 1Head and Neck Neoplasms 1Erectile Dysfunction 1Childhood Solid Tumor 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 24Radiotherapy 21Cisplatin 21Cetuximab 13Carboplatin 11Paclitaxel 8Nivolumab 8durvalumab 7Radiotherapy, Intensity-Modulated 6Docetaxel 6Fluorouracil 5Cyclophosphamide 5zalutumumab 4Everolimus 4Amifostine 4spartalizumab 3fludarabine 3epacadostat 3cemiplimab 3Ipilimumab 3Immune Checkpoint Inhibitors 3Gefitinib 3Filgrastim 3Erlotinib Hydrochloride 3Celecoxib 3Capecitabine 3selpercatinib 2palbociclib 2fludarabine phosphate 2bintrafusp alfa protein, human 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Head and Neck Neoplasms × Cell- and Tissue-Based Therapy × Clear all
NCT06096038 2026-02-20

Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC

UNC Lineberger Comprehensive Cancer Center

Phase 1/2 Recruiting
33 enrolled
Head & Neck

Head and Neck Neoplasms, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡